Efficacy of treatment with intravenous immunoglobulins and pulse therapies with methylprednisolone and cyclophosphamide in patients with active SLE
PDF BG (Български)
PDF ENG

Keywords

Intravenous immunoglobulins, pulse therapies, SLE

How to Cite

Reshkova, V., & Rashkov, R. (2024). Efficacy of treatment with intravenous immunoglobulins and pulse therapies with methylprednisolone and cyclophosphamide in patients with active SLE. Rheumatology (Bulgaria), 32(3), 3-14. https://doi.org/10.35465/32.3.2024.pp3-14

Abstract

Immunoglobulin preparations for intravenous administration (IVIG) contain highly purified native molecules of human IgG, freed from high-molecular aggregates and vasoactive substances stabilized with glucose, maltose, glycine, sorbitol, etc. Intravenous immunoglobulins can be used as adjunctive therapy in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APLS) with recurrent miscarriages. The aim of the clinical observation is to establish the efficacy of the treatment of immunovenin in a scheme, in parallel with pulse therapies with methylprednisolone (MP) and cyclophosphamide (CYC) in patients with active SLE, compared with the application of pulse therapies with methylprednisolone and cyclophosphamide alone. When comparing the effect of treatment with immunovenin 400 mg/kg body weight every 3 months for a period of 12 to 18 months, in parallel with pulse therapies with methylprednisolone and cyclophosphamide 1 g monthly intravenously in disease activity, a significant difference in positive influence on organic brain syndrome, cranial nerve function, arthritis/arthralgias and proteinuria. In both groups, the concentration of anti dsDNA and ACLA decreased to the same extent. Treatment with immunovenin has a positive effect on influencing disease activity in SLE, added to treatment with pulse therapies with methylprednisolone and cyclophosphamide.

https://doi.org/10.35465/32.3.2024.pp3-14
PDF BG (Български)
PDF ENG

References

  1. Baron JK. Efficacy and safety of intravenous immunoglobulin in patients with lupus nephritis: A systematic review of the literature. Autoimmuni Rev 2022, 21, 11.
  2. Mulhearn B, Ian N. Indications for IVIG in rheumatic diseases. Rheumatology 2015; 54:383391 doi:10.1093/rheumatology/keu429
  3. Francioni C, Galeazzi M, Fioravanti A et al. Long-term i.v. Ig treatment in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12:1638.
  4. Rashkov R, Monov S, Ivanova M et al. Consensus SLE. Bulgarian Soc Rheumatol, March 2019.
  5. Nicolò B, Cancelli C, Passalacqua S, De Vito F. Use of Intravenous Immunoglobulin Therapy at Unconventional Doses in Refractory Fulminant Systemic Lupus Erythematosus European Journal of Case Reports in Internal Medicine 2018 Doi: 10.12890/2018_000934
  6. Perricone R, De Carolis C, Kroegler B et al. Intravenous immunoglobulin therapy in pregnant patients affected with systemic lupus erythematosus and recurrent spontaneous abortion. Rheumatology 2008; 47:64651.
  7. Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999; 354: 56970.
  8. Austin HA 3rd, Klippel JH, Balow JE et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314:6149.
  9. Dooley MA, Jayne D, Ginzler EM et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 2011; 365:188695.
  10. Schroeder JO, Zeuner RA, Euler HH, Lo¨ffler H. High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J Rheumatol 1996; 23:715.
  11. Levy Y, Sherer Y, Ahmed A et al. A study of 20 SLE patients
  12. with intravenous immunoglobulin – clinical and serologic response. Lupus 1999; 8:70512.
  13. Hundt M, Manger K, Dorner T et al. Treatment of acute exacerbation of systemic lupus erythematosus with highdose intravenous immunoglobulin. Rheumatology 2000; 39:13012.
  14. Sherer Y, Kuechler S, Jose Scali J et al. Low dose intravenous immunoglobulin in systemic lupus erythematosus: analysis of 62 cases. Isr Med Assoc J 2008;10:557.
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Downloads

Download data is not yet available.